Bold truth: withholding a proven lifesaver from newborns for a research study is not just questionable—it’s unethical. The hepatitis B birth dose vaccine has a long-standing track record of preventing life-threatening liver disease and stopping mother-to-child transmission at birth. Used for more than 30 years, it has been incorporated into national immunization schedules in over 115 countries. Providing this timely birth dose protects individuals and advances national and global elimination goals.
In response to media inquiries, the World Health Organization (WHO) states the following:
WHO is aware of the proposed randomized controlled trial (RCT) on the hepatitis B birth dose vaccine in Guinea-Bissau. After reviewing publicly available information and consulting with experts, WHO has serious concerns about the study’s scientific justification, ethical safeguards, and overall alignment with established research principles involving humans.
Why withholding the vaccine is unethical
- Proven benefit, foreseeable harm: The birth dose has a proven safety record and prevents 70–95% of mother-to-child transmission. A study design that gives a lifesaving intervention to some participants while withholding it from others exposes newborns to serious, potentially irreversible harm, including chronic infection, cirrhosis, and liver cancer.
- No scientific necessity for a no-treatment arm: Placebo or no-treatment designs are only appropriate when no proven intervention exists or when such a design is essential to answer a critical efficacy or safety question. Public information does not indicate these conditions are met.
- Insufficient scientific justification: Public descriptions suggest the protocol does not challenge the established efficacy or impact of the birth dose; instead, it mentions hypothetical safety outcomes without credible evidence of a safety signal justifying participant risk.
- Biased and low-utility design: A single-blind, no-treatment-controlled design raises substantial risk of bias, which would limit interpretation and policy relevance of the results.
- Exploiting scarcity is not ethical: Ethical research requires minimizing risk and ensuring potential benefits for participants. The available description does not demonstrate a mechanism for harm reduction or participant benefit (e.g., screening pregnant women and vaccinating exposed newborns).
At present, based on publicly available information, the trial appears inconsistent with established ethical and scientific standards. Guinea-Bissau has suspended the study for further technical review. WHO offers support to Guinea-Bissau as it considers next steps to accelerate birth dose introduction and strengthen implementation, including:
- Delivering the birth dose within 24 hours, whether births occur at home or in facilities;
- Antenatal HBsAg screening, care linkage, and neonatal prophylaxis;
- Strengthening cold-chain logistics, last-mile delivery, and training for midwives and health workers;
- Monitoring timeliness and coverage, pharmacovigilance, and using data to drive improvements.
WHO remains committed to collaborating with national authorities, researchers, and partners to ensure all newborns—both in Guinea-Bissau and globally—receive timely, evidence-based protection against hepatitis B, and that research in this area adheres to the highest ethical and scientific standards.
/Public Release. This material reflects the point-in-time perspective of the originating organization and may be edited for clarity, style, or length. Mirage.News does not take institutional positions; views and conclusions are those of the authors. View the full article here: https://www.miragenews.com/guinea-bissau-hepatitis-b-vaccine-trial-1619763/
